fda glp-1 safety alert october 2025 May 4, 2025: New study suggests more adverse events associated with compounded GLP-1s than standard formulations – Partnership for Safe Medicines Trends In FDA FY 2025

Weight, tolerability, hydration and GI side effects at each titration step

SURMOUNT trials: tirzepatide The SURMOUNT trials evaluated tirzepatide for weight management

There are also others who are just operating on bad advice because they are listening to governmental agencies about what is best for their health

95% CI, 0.75 to 1.23) or the rate of death (HR, 0.94

Krishnan A, Sims OT, Surapaneni PK, Woreta TA, Alqahtani SA (2023) Risk of adverse cardiovascular outcomes among persons living with HIV and nonalcoholic fatty liver disease: a multicenter matched cohort study

Pricing information is accurate as of the time of writing